MCDONOUGH JOHN (President & CEO) sold 2.3% of their position (6.29K shares) of T2 BIOSYSTEMS, INC. on the open market
Open‑market sale worth $26.9K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 6/8/2018ACC: 0000899243-18-015721
DirectorOfficer· President & CEO
Since Jul 2018
+16.09K
Net shares
Net buyer
$118.6K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
33.13K acquired · 17.04K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−6.29K
Price / share
$4.28
Trade value
$26.93K
% of position
2.3%
2/9/2018
269.13K→262.83K
Common Stock
Direct
Shares
+33.13K
Price / share
—
Trade value
—
% of position
12.6%
6/6/2018
262.83K→295.96K
Common Stock
Direct
Shares
−10.75K
Price / share
$8.53
Trade value
$91.71K
% of position
3.6%
6/6/2018
295.96K→285.21K
Total
Net shares
+16.09K
Net value
-$118.64K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/9/2018 | S · Sale | −6.29K | $4.28 | $26.93K | 2.3% | 269.13K | 262.83K |
| Common Stock Direct | 6/6/2018 | A · Award | +33.13K | — | — | 12.6% | 262.83K | 295.96K |
| Common Stock Direct | 6/6/2018 | F · Tax Withholding | −10.75K | $8.53 | $91.71K | 3.6% | 295.96K | 285.21K |
| Total | +16.09K | -$118.64K | ||||||
Derivative Transactions0
No derivative transactions reported